(Reuters) - Shares of Mylan NV jumped about 17 percent in premarket trading on Wednesday after the U.S. Food and Drug Administration approved the drugmaker's copycat version of Teva Pharmaceutical Industries Ltd's blockbuster multiple sclerosis drug.